Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder.

Mandelkow T, Blessin NC, Lueerss E, Pott L, Simon R, Li W, Wellge B, Debatin NF, Höflmayer D, Izbicki JR, Büscheck F, Luebke AM, Wittmer C, Jacobsen F, Lutz F, Burandt E, Steurer S, Sauter G, Tsourlakis MC, Wilczak W, Hinsch A, Minner S.

Dis Markers. 2019 May 2;2019:2532518. doi: 10.1155/2019/2532518. eCollection 2019.

2.

A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer.

Eichenauer T, Hussein M, Hube-Magg C, Kluth M, Büscheck F, Höflmayer D, Tsourlakis MC, Steurer S, Clauditz TS, Luebke AM, Burandt E, Wilczak W, Hinsch A, Dum D, Beyer B, Steuber T, Huland H, Graefen M, Simon R, Sauter G, Melling N, Schlomm T, Minner S.

Oncotarget. 2019 Mar 1;10(18):1729-1744. doi: 10.18632/oncotarget.26739. eCollection 2019 Mar 1.

3.

5q21 deletion is often heterogeneous in prostate cancer.

Kluth M, Al Kilani Z, Özden C, Hussein K, Frogh S, Möller-Koop C, Burandt E, Steurer S, Büscheck F, Jacobsen F, Luebke AM, Minner S, Tsourlakis MC, Hoeflmayer D, Wittmer C, Schlomm T, Sauter G, Simon R, Wilczak W.

Genes Chromosomes Cancer. 2019 Aug;58(8):509-515. doi: 10.1002/gcc.22730. Epub 2019 Jan 24.

PMID:
30623509
4.

Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer.

Kluth M, Volta H, Hussein M, Taskin B, Frogh S, Möller-Koop C, Büscheck F, Jacobsen F, Tsourlakis MC, Lübke AM, Hinsch A, Clauditz T, Graefen M, Heinzer H, Huland H, Minner S, Sauter G, Wilczak W, Schlomm T, Simon R.

Cancer Manag Res. 2018 Nov 19;10:5909-5917. doi: 10.2147/CMAR.S172637. eCollection 2018.

5.

Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.

Minner S, Lutz J, Hube-Magg C, Kluth M, Simon R, Höflmayer D, Burandt E, Tsourlakis MC, Sauter G, Büscheck F, Wilczak W, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Jacobsen F, Hinsch A, Poos A, Oswald M, Rippe K, König R, Schroeder C.

Prostate. 2019 Feb;79(3):302-311. doi: 10.1002/pros.23736. Epub 2018 Nov 14.

PMID:
30430607
6.

High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases.

Brandi F, Grupp K, Hube-Magg C, Kluth M, Lang D, Minner S, Möller-Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wittmer C, Jacobsen F, Huland H, Steurer S, Lebok P, Hinsch A, Wilczak W, Schlomm T, Simon R.

Oncol Lett. 2018 Nov;16(5):6238-6244. doi: 10.3892/ol.2018.9417. Epub 2018 Sep 7.

7.

Author Correction: Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer.

Heumann A, Kaya Ö, Burdelski C, Hube-Magg C, Kluth M, Lang DS, Simon R, Beyer B, Thederan I, Sauter G, Izbicki JR, Luebke AM, Hinsch A, Jacobsen F, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Schlomm T, Wilczak W.

Sci Rep. 2018 Aug 21;8(1):12821. doi: 10.1038/s41598-018-30975-9.

8.

13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer.

Kluth M, Scherzai S, Büschek F, Fraune C, Möller K, Höflmayer D, Minner S, Göbel C, Möller-Koop C, Hinsch A, Neubauer E, Tsourlakis MC, Sauter G, Heinzer H, Graefen M, Wilczak W, Luebke AM, Burandt E, Steurer S, Schlomm T, Simon R.

Genes Chromosomes Cancer. 2018 Oct;57(10):504-512. doi: 10.1002/gcc.22645. Epub 2018 Aug 20.

PMID:
29923647
9.

Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer.

Hinsch A, Brolund M, Hube-Magg C, Kluth M, Simon R, Möller-Koop C, Sauter G, Steurer S, Luebke A, Angerer A, Wittmer C, Neubauer E, Göbel C, Büscheck F, Minner S, Wilczak W, Schlomm T, Jacobsen F, Clauditz TS, Krech T, Tsourlakis MC, Schroeder C.

World J Urol. 2018 Jun;36(6):877-882. doi: 10.1007/s00345-018-2225-7. Epub 2018 Feb 9.

PMID:
29427004
10.

High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer.

Heumann A, Heinemann N, Hube-Magg C, Lang DS, Grupp K, Kluth M, Minner S, Möller-Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wilczak W, Wittmer C, Jacobsen F, Huland H, Simon R, Schlomm T, Sauter G, Steurer S, Lebok P, Hinsch A.

BMC Cancer. 2018 Jan 5;18(1):37. doi: 10.1186/s12885-017-3956-3.

11.

FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.

Tsourlakis MC, Eleftheriadou A, Stender A, Weigand P, Grupp K, Hube-Magg C, Kluth M, Schroeder C, Steurer S, Hinsch A, Luebke A, Angerer A, Wittmer C, Friedrich E, Göbel C, Büscheck F, Heinzer H, Graefen M, Simon R, Sauter G, Wilczak W, Minner S, Schlomm T, Jacobsen F.

Carcinogenesis. 2017 Dec 7;38(12):1180-1187. doi: 10.1093/carcin/bgx105.

PMID:
29029032
12.

Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer.

Jacobsen F, Kraft J, Schroeder C, Hube-Magg C, Kluth M, Lang DS, Simon R, Sauter G, Izbicki JR, Clauditz TS, Luebke AM, Hinsch A, Wilczak W, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Huland H, Graefen M, Budäus L, Thederan I, Salomon G, Schlomm T, Melling N.

Neoplasia. 2017 Sep;19(9):707-715. doi: 10.1016/j.neo.2017.06.003. Epub 2017 Aug 19.

13.

Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer.

Heumann A, Kaya Ö, Burdelski C, Hube-Magg C, Kluth M, Lang DS, Simon R, Beyer B, Thederan I, Sauter G, Izbicki JR, Luebke AM, Hinsch A, Jacobsen F, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Schlomm T, Wilczak W.

Sci Rep. 2017 May 17;7(1):2056. doi: 10.1038/s41598-017-02279-x. Erratum in: Sci Rep. 2018 Aug 21;8(1):12821.

14.

Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.

Burdelski C, Borcherding L, Kluth M, Hube-Magg C, Melling N, Simon R, Möller-Koop C, Weigand P, Minner S, Haese A, Michl HU, Tsourlakis MC, Jacobsen F, Hinsch A, Wittmer C, Lebok P, Steurer S, Izbicki JR, Sauter G, Krech T, Büscheck F, Clauditz T, Schlomm T, Wilczak W.

Oncotarget. 2017 May 9;8(19):31494-31508. doi: 10.18632/oncotarget.16357.

15.

High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens.

Steurer S, Rico SD, Simon R, Minner S, Tsourlakis MC, Krech T, Koop C, Graefen M, Heinzer H, Adam M, Huland H, Schlomm T, Sauter G, Lumiani A.

BJU Int. 2017 Sep;120(3):365-376. doi: 10.1111/bju.13840. Epub 2017 Apr 11.

16.

Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.

Burdelski C, Fitzner M, Hube-Magg C, Kluth M, Heumann A, Simon R, Krech T, Clauditz T, Büscheck F, Steurer S, Wittmer C, Hinsch A, Luebke AM, Jacobsen F, Minner S, Tsourlakis MC, Beyer B, Steuber T, Thederan I, Sauter G, Izbicki J, Schlomm T, Wilczak W.

Neoplasia. 2017 Apr;19(4):279-287. doi: 10.1016/j.neo.2017.01.005. Epub 2017 Mar 8.

17.

High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer.

Melling N, Rashed M, Schroeder C, Hube-Magg C, Kluth M, Lang D, Simon R, Möller-Koop C, Steurer S, Sauter G, Jacobsen F, Büscheck F, Wittmer C, Clauditz T, Krech T, Tsourlakis MC, Minner S, Huland H, Graefen M, Budäus L, Thederan I, Salomon G, Schlomm T, Wilczak W.

Int J Mol Sci. 2017 Jan 29;18(2). pii: E286. doi: 10.3390/ijms18020286.

18.

Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens.

Sauter G, Clauditz T, Steurer S, Wittmer C, Büscheck F, Krech T, Lutz F, Lennartz M, Harms L, Lawrenz L, Möller-Koop C, Simon R, Jacobsen F, Wilczak W, Minner S, Tsourlakis MC, Chirico V, Weidemann S, Haese A, Steuber T, Salomon G, Matiu M, Vettorazzi E, Michl U, Budäus L, Tilki D, Thederan I, Pehrke D, Beyer B, Fraune C, Göbel C, Heinrich M, Juhnke M, Möller K, Bawahab AAA, Uhlig R, Huland H, Heinzer H, Graefen M, Schlomm T.

Eur Urol. 2018 May;73(5):674-683. doi: 10.1016/j.eururo.2017.01.015. Epub 2017 Jan 20.

PMID:
28117112
19.

βIII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer.

Hinsch A, Chaker A, Burdelski C, Koop C, Tsourlakis MC, Steurer S, Rink M, Eichenauer TS, Wilczak W, Wittmer C, Fisch M, Simon R, Sauter G, Büschek F, Clauditz T, Minner S, Jacobsen F.

Hum Pathol. 2017 Mar;61:210-220. doi: 10.1016/j.humpath.2016.11.005. Epub 2016 Dec 24.

PMID:
28025079
20.

Deletion of 8p is an independent prognostic parameter in prostate cancer.

Kluth M, Amschler NN, Galal R, Möller-Koop C, Barrow P, Tsourlakis MC, Jacobsen F, Hinsch A, Wittmer C, Steurer S, Krech T, Büscheck F, Clauditz TS, Beyer B, Wilczak W, Graefen M, Huland H, Minner S, Schlomm T, Sauter G, Simon R.

Oncotarget. 2017 Jan 3;8(1):379-392. doi: 10.18632/oncotarget.13425.

Supplemental Content

Loading ...
Support Center